Lupus Erythematosus is an indication for drug development with over 330 pipeline drugs currently active. According to GlobalData, preregistered drugs for Lupus Erythematosus have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Lupus Erythematosus compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lupus Erythematosus overview
Lupus erythematosus refers to a group of autoimmune diseases where the immune system attacks healthy tissues, leading to inflammation and damage in various parts of the body. The most common forms are systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE). SLE can affect multiple organs, causing a wide range of symptoms such as fatigue, joint pain, skin rashes, fever, and complications involving the kidneys, heart, or nervous system. DLE primarily affects the skin, presenting as red, scaly, or coin-shaped lesions on the face, scalp, or ears. Diagnosis involves medical history, physical examinations, blood tests, and sometimes skin biopsies. Management includes medications to control inflammation, immune-suppressants, lifestyle adjustments, and careful monitoring to alleviate symptoms and prevent flare-ups in individuals with lupus erythematosus.
For a complete picture of PTSR and LoA scores for drugs in Lupus Erythematosus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
